NASDAQ Closing Cross Calculates U.S. Russell Indexes for

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
NASDAQ Closing Cross Calculates U.S. Russell Indexes for the Eleventh Consecutive Year for Russell's Annual Reconstitution

NEW YORK, June 27, 2014 (GLOBE NEWSWIRE) -- The NASDAQ OMX Group, Inc. (Nasdaq: NDAQ ) today announced the NASDAQ Closing Cross was used for the eleventh consecutive year to rebalance NASDAQ-listed securities in the entire family of U.S. Russell indexes during their annual reconstitution. Approximately 810.6 million shares representing $17.9 billion were executed in the NASDAQ Closing Cross in 575 milliseconds across some 2,304 NASDAQ-listed stocks.

NASDAQ official closing prices (NOCPs) determined by the NASDAQ Closing Cross are widely used throughout the industry, by Russell Investments, Standard & Poor's, Dow Jones, and mutual funds across the country. The NASDAQ Closing Cross mechanism provides market participants with transparency and consistent prices with the dissemination of imbalances, indicative and likely clearing prices every five seconds via the Net Order Imbalance Indicator. NASDAQ OMX's INET technology platform processes accurate closing prices for the industry in microseconds. 

"NASDAQ OMX takes pride in its performance engineering and the ability of our electronic trading platforms to handle large volumes and high velocity quickly and efficiently," said Tom Wittman, Executive Vice President and Head of Global Equities at NASDAQ OMX.  

He added, "As the official platform for NASDAQ-listed stocks in the Russell reconstitution, the NASDAQ Closing Cross generated accurate closing prices during one of the heaviest trading sessions of the year."

The Closing Cross brings together the buy and sell interest in specific NASDAQ, NYSE and NYSE Amex stocks and executes all shares for each stock at a single price, one that reflects the true supply and demand for these securities. All nationally-listed securities are eligible for the NASDAQ Closing Cross.

The Russell U.S. Indexes include only common stocks incorporated in the U.S., its territories, and certain countries or regions offering U.S. companies operational, tax, political or other financial benefits. All Russell U.S. Indexes are subsets of the Russell 3000 ® Index, which represents approximately 98% of the U.S. equity market. Russell U.S. Indexes allow investors to track current and historical market performance by specific market segment (large cap/small cap) or investment style (growth/value/defensive/dynamic). Today, more than $5.2 trillion in assets are benchmarked to the Russell Indexes.

Russell reconstitution day is usually one of the most highly anticipated and heaviest trading days in the U.S. equity market as asset managers seek to reconfigure their portfolios to reflect the composition of Russell's U.S. indexes. The index reconstitution process was completed today and the newly reconstituted index membership will take effect before markets open on Monday, June 30, 2014.

Please visit our website for more information on the NASDAQ Closing Cross .  

About NASDAQ OMX:

NASDAQ OMX (Nasdaq: NDAQ ) is a leading provider of trading, exchange technology, information and public company services across six continents. Through its diverse portfolio of solutions, NASDAQ OMX enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 70 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. NASDAQ OMX is home to more than 3,400 listed companies with a market value of over $8.5 trillion and more than 10,000 corporate clients. To learn more, visit www.nasdaqomx.com .

About Russell Investments:

Russell Investments (Russell) is a global asset manager and one of only a few firms that offers actively managed multi-asset portfolios and services that include advice, investments and implementation. Russell stands with institutional investors, financial advisors and individuals working with their advisors—using the firm's core capabilities that extend across capital market insights, manager research, portfolio construction, portfolio implementation and indexes to help each achieve their desired investment outcomes.

Russell has more than $259 billion in assets under management (as of 3/31/2014) and works with over 2,500 institutional clients, independent distribution partners and individual investors globally. As a consultant to some of the largest pools of capital in the world, Russell has $2.4 trillion in assets under advisement (as of 6/30/2013). It has four decades of experience researching and selecting investment managers and meets annually with more than 2,200 managers around the world. Russell traded more than $1.6 trillion in 2013 through its implementation services business. Russell also calculates approximately 700,000 benchmarks daily covering 98% of the investable market globally, including more than 80 countries and more than 10,000 securities. Approximately $5.2 trillion in assets are benchmarked (as of 12/31/2013) to the Russell Indexes, which have provided investors with 30 years of smarter beta.

Headquartered in Seattle, Washington, Russell operates globally, including through its offices in Seattle, New York, London, Paris, Amsterdam, Sydney, Melbourne, Auckland, Singapore, Seoul, Tokyo, Beijing, Toronto, Chicago, San Diego, Milwaukee and Edinburgh. For more information about how Russell helps to improve financial security for people, visit www.russell.com or follow @Russell_News .

Russell Investment Group is a Washington, USA corporation, which operates through subsidiaries worldwide, including Russell Investments, and is a subsidiary of The Northwestern Mutual Life Insurance Company.  Russell Investments is the owner of the trademarks, service marks and copyrights related to its respective indexes. Russell's indexes are unmanaged and cannot be invested in directly.

Cautionary Note Regarding Forward-Looking Statements

The matters described herein contain forward-looking statements that are made under the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements about the NASDAQ Closing Cross. We caution that these statements are not guarantees of future performance. Actual results may differ materially from those expressed or implied in the forward-looking statements. Forward-looking statements involve a number of risks, uncertainties or other factors beyond NASDAQ OMX's control. These factors include, but are not limited to factors detailed in NASDAQ OMX's annual report on Form 10-K, and periodic reports filed with the U.S. Securities and Exchange Commission. We undertake no obligation to release any revisions to any forward-looking statements.

NDAQG

NASDAQ OMX Media Contacts: Robert Madden +1 646 441 5045 Joseph Christinat +1 646 441 5121

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Novo's Research Unlocks New Insights into Food Noise

Updated Category News Views 356

Unpacking the Science Behind Food Noise When folks think about losing weight, most picture shedding pounds and fitting into those elusive smaller jeans. But get this—there’s a curveball called ‘food noise’ that’s making waves in obesity treatment. Novo Nordisk’s semaglutide injections are shaking things up, cutting down on those persistent thoughts about food....

Continue Reading
Novo's CagriSema Trial Shows Promising Obesity Results

Updated Category News Views 371

Novo's Latest Weight Loss Gamble Well, look what we have here. Novo Nordisk is shaking up the obesity treatment scene with some bold numbers from their REDEFINE 9 trial. The investigational CagriSema combo of amylin analog and GLP-1 receptor agonist has churned out an eyeball-popping near 21% weight loss. For context, we're staring down the barrel of numbers far meatier...

Continue Reading
HONGQI's EHS4 Launch in Europe: Bridging East and West

Updated Category News Views 150

Revving Up a New Chapter: HONGQI in Venice There's a new player in the European automotive scene, and it's rolling in with more style than a Venetian gondola. HONGQI, a name that's been turning gears in China since '58, is packing its suitcases full of Eastern elegance and landing straight in Venice with the all-electric EHS4. On November 16, the brand is set to unveil...

Continue Reading
CARsgen's CAR-T Breakthrough on China's Insurance List

Updated Category News Views 347

A Game Changer for CAR-T Therapies There's a breeze of optimism blowing from Shanghai these days—a rare sensation in this market of endless skirmishes. CARsgen Therapeutics Holdings Limited, a company entrenched in the development of cutting-edge CAR T-cell therapies, just notched a victory. They've announced that their CAR T-cell therapy product, satricabtagene...

Continue Reading
EFICYENT Ventures to Connect at Singapore FinTech Fest

Updated Category News Views 204

Why the Singapore FinTech Festival Matters The world's hardly a stranger to hype, but the Singapore FinTech Festival carries some real weight. From November 18 to 20, 2026, this gig isn't just industry chatter—it's a high-stakes convergence of policymakers, financial institutions, fintech innovators like EFICYENT, and the money folk looking to mold the future of...

Continue Reading
Retirement Dreams Dashed: 61% Withdraw Early

Updated Category News Views 309

Retirement Caught in the Crosshairs Just when you think the path to retirement might clear up, life slaps down older workers with economic reality. A recent LiveCareer survey underscores this financial mess, revealing that 61% of those 50 and older are raiding their own retirement funds to make ends meet. It's enough to make one's head spin. Inflation: The Unwanted Guest...

Continue Reading
EZaccessMD Data Breach: Class Action Lawsuit Looms

Updated Category News Views 238

Data breaches are the bogeyman no one wants lurking in the shadows, and when it’s your personal info at stake, folks rightfully squirm. This recent fiasco at EZaccessMD is one of those unsettling incidents. The word on the street isn't pretty: sensitive medical data has slipped through the cracks, leaving Edelson Lechtzin LLP, a heavyweight in class action maneuvers, to...

Continue Reading
WeaveGrid Powers EVConnectNC: Charging Incentives Launched

Updated Category News Views 177

Transforming Utilities with EVConnectNC In a fresh move by WeaveGrid, North Carolina's Electric Cooperatives have teamed up to roll out EVConnectNC. This innovative program aims to manage the burgeoning demand for electric vehicle (EV) charging in rural and suburban areas under North Carolina's cooperative umbrella. Think of it as a smart way to handle new loads without...

Continue Reading
Servier's Data on Tovorafenib Shows Promise in pLGG

Updated Category News Views 433

New Light on a Critical Challenge Talk about a fight in the dark. Pediatric low-grade glioma (pLGG) is a menace that families dread, an uphill battle with odds that feel relentless. Enter Servier and its four-year updated data on OJEMDA® (tovorafenib), a beacon of hope for kids battling these tricky brain tumors. Results, presented at the SNO meeting, are fresh off the...

Continue Reading
Lilly's Obesity Breakthroughs: A Step Beyond the Scale

Updated Category News Views 243

Pushing the Boundaries of Obesity Treatment Alright, let's cut through the noise and get to what really matters here. Eli Lilly is taking on obesity treatment like it's Clash of the Titans at this year's ObesityWeek 2026 in Washington, D.C. Forget just dropping pounds—Lilly wants to reshape how we think about obesity entirely. They're not just leaning into the scale,...

Continue Reading

Top 5 Most Recently Viewed Articles

Air Canada Navigates Operational Challenges Amid Storms

Updated Category News Views 205

Air Canada's Operational Challenges and Responses Air Canada has recently faced significant operational hurdles due to severe winter weather and an aircraft incident impacting its Toronto Pearson international hub. These challenges have necessitated a comprehensive update from the airline about its current status and ongoing recovery efforts. Recent Weather Impact on...

Continue Reading
Insight into Melexis' Ongoing Share Buy-Back Strategy

Updated Category News Views 128

Melexis Enhances Shareholder Value Through a Strategic Buyback Melexis, a leader in the semiconductor industry, has been actively engaging in a strategic share buy-back program aimed at bolstering shareholder value. This initiative, first announced on December 10, 2024, reflects the company's commitment to enhancing its stock's performance while also optimizing its...

Continue Reading
Value Line, Inc. Launches New Share Repurchase Initiative

Updated Category News Views 220

Value Line, Inc. Announces Stock Repurchase Program Value Line, Inc. (NASDAQ: VALU) recently revealed an exciting development for its shareholders: the Board of Directors has approved a share repurchase program that allows for the buyback of up to $2,000,000 worth of shares. This program comes into effect immediately and marks a significant move that replaces the previous...

Continue Reading
IsoEnergy Expands Stake in Premier American Uranium Inc. Assets

Updated Category News Views 154

IsoEnergy Enhances Investment in Premier American Uranium Inc. IsoEnergy Ltd. (NYSE American: ISOU) (TSX: ISO) has recently expanded its investment in Premier American Uranium Inc. by acquiring a significant number of common shares and warrants. This strategic move further establishes IsoEnergy’s commitment to capitalizing on the promising uranium market amid increasing...

Continue Reading
Texas Attorney General Takes Action Against Insulin Price Fixing

Updated Category News Views 70

Texas Attorney General's Lawsuit Against Insulin Price Fixing Texas Attorney General Ken Paxton has taken significant action by filing a lawsuit against several prominent insulin manufacturers and pharmacy benefit managers (PBMs). The lawsuit highlights allegations of a conspiracy to inflate insulin prices, affecting countless patients who rely on this vital medication....

Continue Reading